Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
CI heads into the back half of August with short sellers quietly rebuilding positions and the analyst community in an uneasy split following a bruising post-earnings reaction in late July.
The most notable shift this week is in short positioning. Bears have added meaningfully — short interest climbed 14% over the past week to 2.1% of the free float, roughly 5.7 million shares. That follows a period of relative calm through mid-August, and the acceleration is sharp enough to warrant attention even if the absolute level remains modest. The borrowing market is no constraint on further additions: availability is extraordinarily loose, with over 260 million shares available to borrow, and borrow cost has edged back up only marginally to 0.45% — barely above the low-fee range seen all month. The ORTEX short score has drifted higher to 33.4, its highest reading in the 10-day window, consistent with the directional rebuild. Options traders are moving the other way. The put/call ratio has dropped to 0.52, modestly below its 20-day average of 0.55 — meaning call demand is actually ticking up relative to recent norms. That mild divergence is worth noting: options positioning looks more constructive than short positioning does.
The Street is split in ways that explain the hesitation in the stock. Thirteen analysts carry buy-equivalent ratings versus five at hold, and the consensus mean target of $341 implies roughly 22% upside from the current $279. But the direction of recent analyst moves has been negative. Jefferies downgraded to Hold in early August, lowering its target to $307. Raymond James cut from Strong Buy to Outperform and trimmed its target to $320. Both downgrades came within days of each other after the Q2 print — when the stock fell nearly 6% on the day and extended that loss to around 7% over the following week. On the other side, Guggenheim raised its target to $361 and Bernstein sits at $381, maintaining the view that the selloff was overdone. Valuation remains a point of argument: the trailing P/E runs at 8.7x and EV/EBITDA at just 7.0x, levels that bulls point to as deeply discounted relative to earnings power. Bears counter with a challenging 2027 setup — soft medical loss ratios, the exit from the exchange market, margin pressure in the PBM and specialty pharmacy business, and an ongoing strategic review of EviCore.
Insider selling adds a modest note of caution. The Chief Administration Officer sold around $6.1 million worth of stock across two transactions in late July and mid-August. CEO David Cordani sold over $13 million in May across multiple tranches. These are routine-looking disposals in size and significance score, but the net 90-day insider flow is entirely negative — no buying on record — which at minimum means insiders have not been stepping in to defend the stock near current levels.
Among peers, the week has been mixed. HUM gained 2% on the week and UNH added 0.7%, while CVS dropped 2.1% and ASTH fell nearly 4%. CI's flat-to-marginal weekly gain of 0.3% keeps it in the middle of the peer pack — neither leading the recovery nor dragging significantly. With the next earnings event pencilled in for October 30, the key question between now and then is whether the short rebuild around 2% of float represents genuine conviction on the bear thesis around 2027 guidance, or simply tactical positioning ahead of what has become a reliably negative earnings-day reaction.
See the live data behind this article on ORTEX.
Open CI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
